

FOR IMMEDIATE RELEASE

**ImQuest Pharmaceuticals announces the appointment of Richard J. Whitley, M.D. as Chairman of its Scientific Advisory Board.**

ImQuest Pharmaceuticals, Inc. announced today the appointment of Richard J. Whitley, M.D. as Chairman of its Scientific Advisory Board.

Dr. Whitley is Professor of Pediatrics, Microbiology and Medicine at the University of Alabama at Birmingham. He holds a variety of positions at the University, including Loeb Scholar in Pediatrics, Director of the Division of Pediatric Infectious Diseases, Vice-Chair of the Department of Pediatrics, Senior Scientist in the Department of Gene Therapy, Senior Scientist in the Cancer Research and Training Center, Associate Director for Clinical Studies in the Center for AIDS Research and the Director of the Center for Biodefense and Emerging Infections, The University of Alabama at Birmingham.

Dr. Whitley is responsible for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group whose role is to perform clinical trials of antiviral therapies directed against medically important viral diseases of children and adults. Dr. Whitley's other research interest is in the translation of molecular biology to clinical application, particularly in the development of human monoclonal antibodies for therapy and engineering of herpes simplex virus for gene therapy. He is a past President of the International Society of Antiviral Research. He has been elected as Fellow to the Infectious Diseases Society of America, American Society of Microbiology, American Society of Clinical Investigation and the Association of American Physicians.

Commenting on the appointment, Robert W. Buckheit, Jr., Ph.D., ImQuest's Chief Scientific Officer, said, "As an expert in his field, Dr. Whitley will provide tremendous value and insight to ImQuest as we advance our portfolio of "first-in-class" infectious disease therapeutics into human clinical trials. We are privileged to welcome Dr. Whitley to our team".

**ImQuest Pharmaceuticals**, Inc. is a privately held U.S. company located in Frederick, Maryland that specializes in the development of novel, "first-in-class" compounds for the treatment of cancer and infectious disease. Information on ImQuest's therapeutic products and corporate development strategy can be found at [www.imquestpharma.com](http://www.imquestpharma.com).

For further information regarding this press release please contact:

Robert W. Buckheit, Jr., Ph.D.  
Chief Scientific Officer  
ImQuest Pharmaceuticals, Inc.  
301-696-0274  
rbuckheit@imquest.com